A new logical insight and putative mechanism behind fluoxetine-induced amenorrhea, hyperprolactinemia and galactorrhea in a case series

Therapeutic Advances in Psychopharmacology

Volumn 3, Issue 6, 2013, Pages 322-334

  Mondal, Somnath ^a   Saha, Indranil ^a   Das, Saibal ^b   Ganguly, Abhrajit ^c   Das, Debasis ^d   Tripathi, Santanu Kumar ^e  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

^b Nalmuri Block Primary Health Centre   (India)

^c NRS MEDICAL COLLEGE   (India)

^d INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^e CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

Author keywords

amenorrhea; fluoxetine; galactorrhea; hyperprolactinemia; selective serotonin reuptake inhibitors (SSRIs)

Indexed keywords

EID: 84997907691     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125313490305     Document Type: Review

References (80)

1. Aizawa T. Hinkle P. (1985) Thyrotropin-releasing hormone rapidly stimulates a biphasic secretion of prolactin and growth hormone in GH4C1 rat pituitary tumor cells. Endocrinology 116: 73–82.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Available at: http://www.psychiatry.org/practice/dsm (accessed 12 December 2012).
3. Amsterdam J. Garcia-Espana F. Goodman D. Hooper M. Hornig-Rohan M. (1997) Breast enlargement during chronic antidepressant therapy. J Affect Disord 46: 151–156.
4. Arya D. (1994) Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatr 165: 728–733.
5. Arya D. Taylor W. (1995) Lactation associated with fluoxetine treatment. Austr NZ J Psychiatr 29: 697.
6. Attenburrow M. Mitter P. Whale R. Terao T. Cowen P. (2001) Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 155: 323–326.
7. Ben-Jonathan N. (1994) Regulation of prolactin secretion. In Imura H. (ed.), The Pituitary Gland, 2nd edn. New York: Raven Press, Ltd, pp. 261–283.
8. Benker G. Jaspers C. Hausler G. Reinwein D. (1990) Control of prolactin secretion. Klin Wochen 68: 1157–1167.
9. Bjoro T. Sand O. Ostberg B. Gordeladze J. Torjesen P. Gautvik K. Haug E. (1990) The mechanisms by which vasoactive intestinal peptide (VIP) and thyrotropin releasing hormone (TRH) stimulate prolactin release from pituitary cells. Biosci Rep 10: 189–199.
10. Bondolfi G. Rubin C. Bryois C. Eap C. (1997) [Galactorrhoea induced by a pharmacodynamic interaction between citalopram, alprazolam and tramadol: a case report]. Therapie 52: 76–77.
11. Bonin B. Vandel P. Sechter D. Bizouard P. (1997) Paroxetine and galactorrhea. Pharmacopsychiatry 30: 133–134.
12. Bronzo M. Stahl S. (1993) Galactorrhea induced by sertraline. Am J Psychiatr 150: 1269–1270.
13. Brunswick D. Amsterdam J. Fawcett J. Quitkin F. Reimherr F. Rosenbaum J. et al. (2002) Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment. J Affect Disord 68: 243–249.
14. Buke W. Hendricks S. McArthur-Miller D. Jacques D. Bessette D. McKillup T. et al. (2000) Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial. J Clin Psychopharmacol 20: 423–427.
15. Canan F. AydýnoÐlu Ü. Sinani G. (2011) Reversible normoprolactinemic galactorrhea induced by fluoxetine. Poster Presentations. Book of abstracts of the fourth international congress on psychopharmacology. Turk Assoc Psychopharmacol S147: 181.
16. Carter J. Tyson J. Tolis G. Van Vliet S. Faiman C. Friesen H. (1978) Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 299: 847–852.
17. Cowen P. Sargent P. (1997) Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 11: 345–348.
18. Davenport E. Velamoor R. (2002) A case of paroxetine-induced galactorrhea. Can J Psychiatry–Rev Can Psychiatrie 47: 890–891.
19. Dubovsky S. (1994) Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatr 55: 34–44.
20. Dulchin M. Oquendo M. Malone K. Ellis S. Li S. Mann J. (2001) Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine. Neuropsychopharmacology 25: 395–401.
21. Eli Lilly (1995) Prozac (fluoxetine hydrochloride) Product Information. Dista Products Company, a division of the Eli Lilly Industries, Inc., Carolina, Puerto Rico, a subdivision of Eli Lilly and Co., Indianapolis, IN.
22. Emiliano A. Fudge J. (2004) From galactorrhea to osteopenia, Rethinking serotonin-prolactin interactions. Neuropsychopharmacology 29: 833–846.
23. Eric H. Alicia K. Stephen M. (2003) A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatr 4: 30–34.
24. Fuchs E. Mansky T. Stock K. Vijayan E. Wuttke W. (1984) Involvement of catecholamines and glutamate in GABAergic mechanism regulatory to luteinizing hormone and prolactin secretion. Neuroendocrinology 38: 484–489.
25. Gomez F. Reyes F. Faiman C. (1977) Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med 62: 648–660.
26. Gonzalez E. Minguez L. Sanguino R. (2000) Galactorrhea after paroxetine treatment. Pharmacopsychiatry 33: 118.
27. Goodman W. Price L. Rasmussen S. Mazure C. Fleischmann R. Hill C. et al. (1989) The Yale–Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006–1011.
28. Goodnick P. Goldstein B. (1998) Selective serotonin reuptake inhibitors in affective disorders I. Basic pharmacology. J Psychopharmacol 12: S5–S20.
29. Goren M. Kuçukibrahimoglu E. Berkman K. Terzioglu B. (2007) Fluoxetine partly exerts its actions through GABA: a neurochemical evidence. Neurochem Res 32: 1559–1565.
30. Gulsun M. Evrensel A. Verim S. (2006) Galactorrhea during escitalopram treatment: a case report. Bull Clin Psychopharmacol 16: 39–41.
31. Gulsun M. Algul A. Semiz U. Ates M. Doruk A. Ebrinc S. et al. (2007) A case with euprolactinemic galactorrhea induced by escitalopram. Int J Psychiatry Med 37: 275–278.
32. Guze B. Gitlin M. (1994) New antidepressants and the treatment of depression. J Fam Pract 38: 49–57.
33. Hall J. Naranjo C. Sproule B. Herrmann N. (2003) Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. J Clin Psychopharmacol 23: 349–357.
34. Hall M. (1994) Breast tenderness and enlargement induced by sertraline. Am J Psychiatry 151: 1395–1396.
35. Harlow B. Wise L. Otto M. Soares C. Cohen L. (2003) Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause. The Harvard Study of Moods and Cycles. Arch Gen Psychiatr 60: 29–36.
36. Hedlung J. Vieweg B. (1979) The Hamilton rating scale for depression: a comprehensive review. J Operat Psychiat 10: 149–165.
37. Henry M. Schmidt M. Hennen J. Villafuerte R. Butman M. Tran P. et al. (2005) A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS Study. Neuropsychopharmacology 30: 1576–1583.
38. Hyttel J. (1984) Experimental pharmacology of selective 5-HT reuptake inhibitors: differences and similarities. Clin Neuropharmacol 7: 866–867.
39. Iancu I. Ratzoni G. Weitzman A. Apter A. (1992) More fluoxetine experience. J Am Acad Child Adolesc Psychiatry 31: 755–756.
40. Jeffries J. Bezchlibnyk-Butler K. Remington G. (1992) Amenorrhea and galactorrhea associated with fluvoxamine in a loxapinetreated patient. J Clin Psychopharmacol 12: 296–297.
41. Kaplan J. Manuck S. (2004) Ovarian dysfunction, stress, and disease: a primate continuum. ILAR J 45: 89–115.
42. Kiss J. Halasz B. (1986) Synaptic connections between serotoninergic axon terminals and tyrosine hydroxylase-immunoreactive neurons in the arcuate nucleus of the rat hypothalamus. A combination of electron microscopic autoradiography and immunocytochemistry. Brain Res 364: 284–294.
43. Laine K. Anttila M. Heinonen E. Helminen A. Huupponen R. Mäki-Ikola O. et al. (1997) Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 20: 419–433.
44. Lesaca T. (1996) Sertraline and galactorrhea. J Clin Psychopharmacol 16: 333–334.
45. Lightman S. Young W. III (1987) Vasopressin, oxytocin, dynorphin, enkephalin and corticotrophin-releasing factor mRNA stimulation in the rat. J Physiol 394: 23–39.
46. Lobo R. Carmina E. (2000) The Importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132: 989–993.
47. McCann S. Lumpkin M. Mizunuma H. Khorram O. Samson W. (1984) Recent studies on the role of brain peptides in control of anterior pituitary hormone secretion. Peptides 5: 3–7.
48. Mirkes S. Bethea C. (2001) Oestrogen, progesterone and serotonin converge on GABAergic neurones in the monkey hypothalamus. J Neuroendocrinol 13: 182–192.
49. Mitan L. (2004) Menstrual dysfunction in anorexia nervosa. J Pediatr Adolesc Gynecol 17: 81–85.
50. Mogg R. Samson W. (1990) Interactions of dopaminergic and peptidergic factors in the control of prolactin release. Endocrinology 126: 728–735.
51. Montgomery S. Åsberg M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.
52. Morrison J. Remick R. Leung M. Wrixon K. Bebb R. (2001) Galactorrhea induced by paroxetine. Can J Psychiatry–Rev Can Psychiatrie 46: 88–89.
53. Naranjo C. Busto U. Sellers E. Sandor P. Ruiz I. Roberts E. et al. (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239–245.
54. Nicholas L. Dawkins K. Golden R. (1998) Psychoneuroendocrinology of depression. Prolactin. Psychiatr Clin North Am 21: 341–358.
55. Nierenberg A. Farabaugh A. Alpert J. Gordon J. Worthington J. Rosenbaum J. et al. (2000) Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 157: 1423–1428.
56. Ondo J. Dom R. (1986) The arcuate nucleus: a site for gammaaminobutyric acid regulation of prolactin secretion. Brain Res 381: 43–48.
57. Otero M. Ripoll A. Pares G. Basagana G. (2002) Galactorrhea associated with paroxetine. Med Clin 118: 758–759.
58. Pablos E. Martin L. Fernandez M. Andres R. (2001) A case of galactorrhea after treatment with citalopram. Actas Esp Psiquiatr 29: 414.
59. Papakostas G. Clain A. Ameral V. Baer L. Brintz C. Smith W. et al. (2010) Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Intern Clin Psychopharmacol 25: 17–21.
60. Perez V. Dolors P. Inmaculada G. Enric A. Francesc A. Trastorns Afectius G. (2001) Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol 21: 36–45.
61. Peterson M. (2001) Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 76: 215–216.
62. Petit A. Piednoir D. Germain M. Trenque T. (2003) [Drug-induced hyperprolactinemia: a case-non-case study from the national pharmacovigilance database]. Therapie 58: 159–163.
63. Petrić D. Peitl M. Peitl V. (2011) High doses alprazolam induced amenorrhoea and galactorrhoea. Psychiatr Danub 23: 123–124.
64. Rasgon N. Altshuler L. Gudeman D. Burt V. Tanavoli S. Hendrick V. et al. (2000) Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. J Clin Psychiatry 61: 173–178.
65. Rasgon N. Rao R. Hwang S. Altshuler L. Elman S. Zuckerbrow-Miller J. et al. (2003) Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 74: 299–304.
66. Rossi A. Barraco A. Donda P. (2004) Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry 3: 2.
67. RxList Inc. (2007) Prozac Pharmacology, Pharmacokinetics, Studies, Metabolism. Available at: http://www.rxlist.com/prozac-drug.htm#cp (accessed on 1 January 2013).
68. Samson W. Bianchi R. Mogg R. Rivier J. Vale W. Melin P. (1989) Oxytocin mediates the hypothalamic action of vasoactive intestinal peptide to stimulate prolactin secretion. Endocrinology 124: 812–819.
69. Samson W. Lumpkin M. McCann S. (1986) Evidence for a physiological role for oxytocin in the control of prolactin secretion. Endocrinology 119: 554–560.
70. Segal S. Yaffe H. Laufer N. Ben-David M. (1979) Male hyperprolactinemia: effects on fertility. Fertility Sterility 32: 556–561.
71. Seppala M. (1978) Prolactin and female reproduction. Ann Clin Res 10: 164–170.
72. Shim S. Lee Y. Lee E. (2009) A case of galactorrhea associated with excitalopram. Psychiatry Investig 6: 230–232.
73. Spigset O. Mjorndal T. (1997) The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status. J Clin Psychopharmacol 17: 292–297.
74. Stahl S. (2000) Classical antidepressants, serotonin selective reuptake inhibitors, and noradrenergic reuptake inhibitors. In: Essential Psycho Pharmacology, vol. 6, 2nd edn. New York: Cambridge University Press, 2000, pp. 199–244.
75. Tatsumi M. Groshan K. Blakely R. Richelson E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249–258.
76. Urban R. Veldhuis J. (1991) A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Am J Obstet Gynecol 164: 147–152.
77. Wagner E. Goudreau J. Moore K. Lookingland K. (1994) GABAergic regulation of tuberoinfundibular dopaminergic neurons in the male rat. Brain Res 659: 194–200.
78. Wanke I. Rorstad O. (1990) Receptors for vasoactive intestinal peptide in rat anterior pituitary glands: localization of binding to lactotropes. Endocrinology 126: 1981–1988.
79. Wong D. Bymaster F. Engleman E. (1995) Minireview: Prozac (Fluoxetine, Lilly 110140), the first selective selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57: 411–441.
80. Young E. Korzun A. (2002) The hypothalamic–pituitary–gonadal axis in mood disorders. Endocrinol Metab Clin North Am 31: 63–78.